Literature DB >> 22661519

Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much.

Stephen I Rennard, Kristina L Bailey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22661519      PMCID： PMC5448605          DOI： 10.1164/rccm.201202-0227ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  11 in total

1.  Impact of preventing exacerbations on deterioration of health status in COPD.

Authors:  S Spencer; P M A Calverley; P S Burge; P W Jones
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

2.  Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary.

Authors:  Nancy K Leidy; Teresa K Wilcox; Paul W Jones; Laurie Roberts; John H Powers; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2010-09-02       Impact factor: 21.405

3.  Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure.

Authors:  Nancy Kline Leidy; Teresa K Wilcox; Paul W Jones; Lindsey Murray; Randall Winnette; Kellee Howard; Jennifer Petrillo; John Powers; Sanjay Sethi
Journal:  Value Health       Date:  2010-12       Impact factor: 5.725

4.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 5.  Toward a consensus definition for COPD exacerbations.

Authors:  R Rodriguez-Roisin
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

6.  Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.

Authors:  Alex J Mackay; Gavin C Donaldson; Anant R C Patel; Paul W Jones; John R Hurst; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

7.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

8.  Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Catherine Wrona; Karen Eschberger; Phyllis Lobbins; Xueya Cai; Timothy F Murphy
Journal:  Am J Respir Crit Care Med       Date:  2007-12-13       Impact factor: 21.405

9.  Development and first validation of the COPD Assessment Test.

Authors:  P W Jones; G Harding; P Berry; I Wiklund; W-H Chen; N Kline Leidy
Journal:  Eur Respir J       Date:  2009-09       Impact factor: 16.671

10.  The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study.

Authors:  James W Dodd; Lauren Hogg; Jane Nolan; Helen Jefford; Amy Grant; Victoria M Lord; Christine Falzon; Rachel Garrod; Cassandra Lee; Michael I Polkey; Paul W Jones; William D-C Man; Nicholas S Hopkinson
Journal:  Thorax       Date:  2011-03-12       Impact factor: 9.139
View more
  2 in total

1.  A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK.

Authors:  Joshua D Campbell; John E McDonough; Julie E Zeskind; Tillie L Hackett; Dmitri V Pechkovsky; Corry-Anke Brandsma; Masaru Suzuki; John V Gosselink; Gang Liu; Yuriy O Alekseyev; Ji Xiao; Xiaohui Zhang; Shizu Hayashi; Joel D Cooper; Wim Timens; Dirkje S Postma; Darryl A Knight; Marc E Lenburg; James C Hogg; Avrum Spira
Journal:  Genome Med       Date:  2012-08-31       Impact factor: 11.117

2.  Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Patricia García-Sidro; Alonso Fernández-Nistal; María Jesús Buendía; María José Espinosa de los Monteros; Jesús Molina
Journal:  Health Qual Life Outcomes       Date:  2013-08-29       Impact factor: 3.186
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.